WIRB-Copernicus Group (WCG), a provider of solutions that measurably improve the quality and efficiency of clinical research, has announced an industry-transforming agreement with karmadata, the market leader in clinical trial database and decision support applications.

WCG will acquire a suite of proprietary applications designed to facilitate the management of clinical trial data, as well as an exclusive license to use karmadata’s extensive global library of clinical trial investigator and site data.

“Our clients continue to look for ways to accelerate patient access to innovative medicines by increasing the productivity of the drug development process,” said Donald A. Deieso, Ph.D., chairman and CEO of WCG. “Through the acquisition of karmadata’s proprietary clinical trials database and big data technologies, we will be able to help them drive an even greater return on investment in the conduct of clinical trials.”

WCG provides the industry’s most comprehensive and quality-driven solutions to increase the speed of clinical trial activation. karmadata is widely recognized as the global leader in the organization and analysis of “big data” in healthcare. The addition of karmadata’s global investigator data to WCG’s existing investigator/site database (WCG InSite) will result in an offering that will provide biopharmaceutical companies and CROs with unprecedented information with which to plan and conduct their site feasibility activities.

Sean Power, founder and CEO of karmadata, said, “At karmadata, it is our mission to use data and technology to transform the healthcare industry. We are at a tipping point, and WCG is in a unique position to fundamentally change how sponsors, physicians, and patients experience a clinical trial. WCG has a patient-first mentality that makes me proud to be part of their family.”